8-K: LAVA Therapeutics to be Acquired by XOMA Royalty

LAVA Therapeutics announced an agreement to be acquired by XOMA Royalty Corporation for $1.16-$1.24 per share plus a contingent value right, alongside discontinuing its LAVA-1266 program and reporting Q2 2025 financial results.

Summary

• LAVA Therapeutics entered a definitive share purchase agreement to be acquired by XOMA Royalty Corporation.
• The acquisition price is between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) for potential contingent cash payments related to partnered and unpartnered assets.
• XOMA Royalty Corporation will commence a tender offer by August 15, 2025, to acquire all of LAVA's outstanding common shares.
• The acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholders.
• LAVA Therapeutics decided to discontinue the development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome, and the wind-down of the program has been initiated.
• Partnered programs, JNJ-89853413 with Johnson & Johnson and PF08046052 with Pfizer, are continuing their Phase 1 clinical trials.
• Cash, cash equivalents, and short-term investments decreased to $56.2 million as of June 30, 2025, from $76.6 million as of December 31, 2024.
• Revenue from contracts with customers was zero for the quarters ended June 30, 2025 and 2024, and zero for the six months ended June 30, 2025, compared to $7.0 million for the six months ended June 30, 2024 (from a Pfizer milestone payment).
• Research and development expenses were $4.7 million for Q2 2025 (down from $6.0 million in Q2 2024) and $8.9 million for H1 2025 (down from $11.6 million in H1 2024), primarily due to restructuring and program discontinuation.
• General and administrative expenses were $2.6 million for Q2 2025 (down from $3.4 million in Q2 2024) and $6.0 million for H1 2025 (down from $6.8 million in H1 2024), due to lower headcount and streamlining, partially offset by US GAAP transition costs and severance.
• Net loss was $8.6 million for Q2 2025 ($0.32 per share) compared to $8.3 million for Q2 2024 ($0.31 per share).
• Net loss was $12.1 million for H1 2025 ($0.45 per share) compared to $8.9 million for H1 2024 ($0.33 per share).
• The company believes it may have been classified as a Passive Foreign Investment Company (PFIC) for its taxable year ended December 31, 2024, and may be classified as a PFIC in the current taxable year ending December 31, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the acquisition provides an exit for shareholders, the discontinuation of a key clinical program (LAVA-1266) and the potential PFIC status are significant negative developments. The financial results show increased losses and decreased cash, indicating ongoing operational challenges that led to the strategic review and sale. The CVR offers potential upside but is non-transferable and uncertain.

Positives

• A definitive agreement to be acquired by XOMA Royalty Corporation provides a clear exit strategy and liquidity for shareholders.
• The acquisition includes a cash payment of $1.16 to $1.24 per share, plus a non-transferable contingent value right (CVR) for potential future payments from partnered and unpartnered assets.
• The Board of Directors unanimously determined that the acquisition is in the best interests of all shareholders and has approved the proposed transaction.
• The outstanding innovation credit from Rijksdienst voor Ondernemend Nederland (RVO) was forgiven in March 2025, which positively impacted other income.
• Partnered programs with Johnson & Johnson (JNJ-89853413) and Pfizer (PF08046052) are continuing to enroll patients in their respective Phase 1 trials.

Negatives

• The decision was made to discontinue the Phase 1 clinical trial and initiate the wind-down of the LAVA-1266 program for acute myeloid leukemia and myelodysplastic syndrome.
• Cash, cash equivalents, and short-term investments significantly decreased by $20.4 million, from $76.6 million as of December 31, 2024, to $56.2 million as of June 30, 2025.
• Net loss increased to $8.6 million in Q2 2025 from $8.3 million in Q2 2024, and to $12.1 million in H1 2025 from $8.9 million in H1 2024.
• Revenue from contracts with customers was zero for Q2 2025 and H1 2025, a decrease from $7.0 million in H1 2024.
• The company believes it may have been classified as a Passive Foreign Investment Company (PFIC) for 2024 and may be classified as such for 2025, which could result in adverse U.S. federal income tax consequences for U.S. investors.
• Other expense, net of $1.3 million in Q2 2025 compared to other income, net of $1.2 million in Q2 2024, primarily due to foreign exchange loss and lower interest rates.

Risks

• The company believes it may have been classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for its taxable year ended December 31, 2024, and may be classified as a PFIC in the current taxable year ending December 31, 2025, which could result in adverse U.S. federal income tax consequences to U.S. investors.
• There is no assurance that the company will not be deemed a PFIC for the current taxable year or in the future, as PFIC status depends on the composition of income and assets and the market value of assets.
• The acquisition transactions may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and the price of its common shares.
• There is a risk of delay or failure of the conditions of the tender offer to be satisfied (or waived), including insufficient common shares of LAVA being tendered.
• The possibility exists that competing offers for the company will be made.
• Significant costs are associated with the acquisition transactions.
• Any shareholder or other litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Activities related to the Contingent Value Right (CVR) Agreement may not result in any value to LAVA's shareholders.
• Prior to the completion of the transactions, LAVA's or XOMA's business may experience significant disruptions due to transaction-related uncertainty.
• The announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Purchase Agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities (e.g., the Russian invasion of Ukraine and the conflict in the Middle East).

Future Outlook

The company expects the acquisition by XOMA Royalty Corporation to close in the fourth quarter of 2025, subject to customary closing conditions and shareholder approval. It also believes it may be classified as a Passive Foreign Investment Company (PFIC) for the current taxable year ending December 31, 2025.

Management Comments

• "We are pleased to announce that LAVA has recently entered into a definitive agreement to be acquired by XOMA Royalty Corporation." Steve Hurly, Chief Executive Officer of LAVA.
• "This deal is the outcome of a comprehensive and diligent strategic review process by management and our Board of Directors, conducted under the guidance of our legal and financial advisors, with the objective of maximizing value for our shareholders while supporting the sustained success of LAVA’s business." Steve Hurly, Chief Executive Officer of LAVA.
• "Our Board of Directors has unanimously determined that the deal is in the best interests of all of our shareholders and has approved the proposed acquisition." Steve Hurly, Chief Executive Officer of LAVA.

Industry Context

The acquisition of LAVA Therapeutics by XOMA Royalty Corporation reflects a trend in the biopharmaceutical industry where smaller, clinical-stage companies, especially those with early-stage assets or facing financial pressures, are acquired by larger entities or royalty companies seeking to diversify their portfolios or gain access to specific therapeutic platforms. The discontinuation of the LAVA-1266 program highlights the high-risk nature of drug development, where programs are often terminated due to efficacy, safety, or strategic reasons, even after entering clinical trials. The continued progress of partnered programs with Johnson & Johnson and Pfizer, however, underscores the value of strategic collaborations in de-risking and advancing novel therapies in immuno-oncology.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark LAVA's financial performance or clinical program progress against industry standards.
• The acquisition price of $1.16 to $1.24 per share, plus a CVR, would need to be assessed against recent acquisitions of clinical-stage immuno-oncology companies with similar pipeline stages and technology platforms to determine if it represents a premium or discount.
• The discontinuation of a Phase 1 program like LAVA-1266 is a common occurrence in the highly competitive and risky drug development landscape, where a significant percentage of early-stage assets do not advance to later phases.
• The cash burn rate and net loss figures are typical for a clinical-stage biotech company that is not yet generating significant product revenue, but their sustainability would typically be compared to the company's cash runway and industry averages for similar-stage companies.

Legal Proceedings

• Risk that any shareholder or other litigation in connection with the acquisition transactions may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders will receive a cash payment of $1.16 to $1.24 per share plus a contingent value right, providing liquidity and a potential future payout. However, the CVR is non-transferable and its value is uncertain. The potential PFIC status could have adverse tax consequences for U.S. investors.
• Employees have been impacted by restructuring activities leading to a reduction in headcount. The acquisition may lead to further changes in employment.
• Patients with acute myeloid leukemia and myelodysplastic syndrome will no longer have LAVA-1266 as a potential treatment option from LAVA due to its discontinuation. Patients in ongoing partnered trials (J&J, Pfizer) will continue to be enrolled.
• The announcement and pendency of the acquisition may make it more difficult to establish or maintain relationships with suppliers, vendors, and business partners.
• The forgiveness of the Rijksdienst voor Ondernemend Nederland (RVO) credit balance is a positive for the company's financial position relative to that specific creditor.

Next Steps

• XOMA Royalty Corporation will commence a tender offer by August 15, 2025, to acquire all outstanding common shares.
• The closing of the acquisition is expected in the fourth quarter of 2025.
• An extraordinary general meeting of shareholders will be held to vote on certain proposed resolutions related to the acquisition.
• The wind-down of the LAVA-1266 program has been initiated.
• Johnson & Johnson and Pfizer are continuing to enroll patients in Phase 1 trials for their respective partnered programs (JNJ-89853413 and PF08046052).

Key Dates

Recommendation

Given the definitive agreement for acquisition via a tender offer, the stock's price will likely trade close to the offer price of $1.16 to $1.24 per share, plus the potential CVR value. For existing shareholders, holding shares until the tender offer commences and then tendering them would be the most logical action to realize the acquisition value. There is limited upside beyond the offer price, and potential downside if the deal falls through, though the Board has unanimously approved it.

Keywords

LAVA Therapeutics, XOMA Royalty Corporation, Acquisition, Tender Offer, Biopharmaceutical, Immuno-oncology, Gammabody, Bispecific T cell engagers, Clinical trial, LAVA-1266, JNJ-89853413, PF08046052, AML, MDS, Solid tumors, EGFR, CD33, Financial results, Q2 2025, SEC filing, 8-K, PFIC, Contingent Value Right, LVTX